Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 18, 2013

View Archived Issues

Researchers from the University of California present two novel ROR1-targeting therapies

LY-2928057 dose-dependently increases serum iron levels in vivo

Moberg reports interim data from phase II study of MOB-015 for onychomycosis

BioLineRx reports initial phase II data for BL-8040 in AML

Millennium Pharmaceuticals begins phase I study of TAK-659

arGEN-X reports findings from dose-escalation part of phase Ib study of ARGX-110

Retrophin agrees to acquire Kyalin Biosciences

Evotec and Yale establish DNA repair research collaboration

Chimeric antigen receptor therapy for pediatric ALL targets the TSLPR

Novel BTK inhibitors patented by Pharmascience

Chinese researchers prepare new SGLT2 inhibitors for diabetes

Ares Trading presents novel BACE1 inhibitors for neurodegenerative disorders

Navidea Biopharmaceuticals submits supplemental NDA to FDA for Lymphoseek

Scientists at Phenex Pharmaceuticals disclose new ROR-gamma modulators

AnaptysBio forms antibody development agreement with Momenta Pharmaceuticals

Capricor Therapeutics cleared to begin phase II portion of ALLSTAR trial

Hoffmann-La Roche synthesizes new PDE10A inhibitors for psychotic disorders

Studies in different species reveal developmental role for Lhx6 in schizophrenia

Boehringer Ingelheim patents new GPR40 agonists for diabetes

New NPFF1 receptor antagonists for pain designed by French group

MultiStem receives orphan drug designation in Europe

Novel radioligand described for imaging Abeta in AD

FDA approves Prosigna breast cancer gene signature assay

Ixico offers business update

PIVKA-II test kit for HCC launched in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...